XXEC Inc. lifted its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 487.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 545,020 shares of the company’s stock after purchasing an additional 452,185 shares during the quarter. Novo Nordisk A/S comprises about 3.9% of XXEC Inc.’s portfolio, making the stock its 13th biggest position. XXEC Inc.’s holdings in Novo Nordisk A/S were worth $20,029,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smith Chas P & Associates PA Cpas grew its stake in shares of Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after acquiring an additional 207,959 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at about $3,171,000. CIBC Bancorp USA Inc. purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $19,519,000. Romano Brothers AND Company raised its position in shares of Novo Nordisk A/S by 704.0% in the 4th quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock valued at $1,742,000 after purchasing an additional 29,978 shares during the last quarter. Finally, Capital Investment Counsel LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $3,727,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.
Trending Headlines about Novo Nordisk A/S
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Shantha Biologics said it signed an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India, signaling continued demand and operational expansion for NVO’s diabetes/weight-loss product supply chain. Shantha Biologics Announces Cartridge Fill-Finish Collaboration
- Positive Sentiment: Medicare will begin covering obesity drugs for eligible seniors under a temporary program, which could expand access to GLP-1 treatments and broaden the addressable market for Novo Nordisk’s Wegovy franchise. Medicare will start covering obesity drugs for the first time. Here’s what patients should know
- Positive Sentiment: Citi said Novo Nordisk’s oral Wegovy pill is gaining prescriptions quickly in the U.S., suggesting strong early traction in the competitive oral GLP-1 market. Citi says Wegovy pill outpacing rivals as oral GLP-1 race heats up
- Neutral Sentiment: Several articles discussed Novo Nordisk versus rivals like Viking and broader obesity/biotech trends, but these were mostly comparative or thematic pieces rather than direct company-specific catalysts. Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
- Neutral Sentiment: Novo Nordisk also announced an ongoing share repurchase program, which supports capital returns but is not a major new surprise. Novo Nordisk A/S – share repurchase programme
- Negative Sentiment: Coverage focusing on Eli Lilly’s broader growth prospects and new launches highlights intensifying competition in the GLP-1 market, which could pressure Novo Nordisk’s long-term market share. Can Eli Lilly’s New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
Analysts Set New Price Targets
Novo Nordisk A/S Trading Down 0.9%
Novo Nordisk A/S stock opened at $47.92 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $71.79. The company has a market capitalization of $213.96 billion, a price-to-earnings ratio of 11.25, a price-to-earnings-growth ratio of 4.37 and a beta of 0.78. The stock has a 50-day moving average price of $44.09 and a 200 day moving average price of $45.82.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion for the quarter. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current year.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Further Reading
- Five stocks we like better than Novo Nordisk A/S
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
